This trial is active, not recruiting.

Conditions epilepsy, localization-related epilepsy, infantile spasms, lennox-gastaut syndrome, polymicrogyria, periventricular heterotopias
Sponsor University of California, San Francisco
Collaborator National Institute of Neurological Disorders and Stroke (NINDS)
Start date November 2007
End date December 2013
Trial size 4150 participants
Trial identifier NCT00552045, 1R01NS053998, 1R01NS053998-01A1, CRC


The purpose of this study is to collect detailed information about the characteristics and genetics of a large number of individuals with epilepsy.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
individuals with epilepsy

Primary Outcomes

EPGP will recruit persons with specific forms of epilepsy. DNA will be isolated from participants' blood and genetic variants associated with common forms of epilepsy will be identified.
time frame: over 4.5 years

Eligibility Criteria

Male or female participants up to 60 years old.

Inclusion Criteria: - Current age from 4 weeks to 60 years. - Clear diagnosis of epilepsy, i.e., a lifetime history of two or more unprovoked seizures. - Age at first unprovoked seizure younger than 40 years. - High quality clinical and laboratory data (i.e., neuroimaging, EEG) must be available throughout the patient's history - All patients with localization-related epilepsy (LRE) or idiopathic generalized epilepsy (IGE) must have a first-degree relative (parent, child, or sibling) with non-symptomatic (idiopathic or cryptogenic) epilepsy who is willing and available to participate. - All patients with infantile spasms (IS), Lennox-Gastaut syndrome (LGS), or malformations of cortical development (MCD) must have both biological parents available and willing to participate. Exclusion Criteria: - Clinical and laboratory data do not allow a clear determination of whether the patient has epilepsy, or whether the diagnosis is LRE, IGE, IS, LGS, or MCD. - Exclusively febrile seizures or other acute symptomatic seizures. - Identified antecedent cause of epilepsy (i.e., a structural or metabolic insult to the CNS prior to the first unprovoked seizure, such as stroke, brain tumor, severe head trauma, etc., or a progressive neurodegenerative disorder). - Recognized genetic syndrome (e.g., tuberous sclerosis, neurofibromatosis, Rett's or Angelman's syndromes) or chromosomal abnormality. (e.g., aneuploidies, unbalanced translocations, or chromosomal deletions and duplications detectable by conventional medical karyotyping).

Additional Information

Official title Epilepsy Phenome/Genome Project: A Phenotype/Genotype Analysis of Epilepsy
Principal investigator Daniel Lowenstein, MD
Description Epilepsy is one of the most common neurological disorders and is a major public health concern. Approximately 30 percent of people with epilepsy have medically intractable epilepsy, and the medical and social consequences of the disorder are enormous. Treatments developed for epilepsy have largely been experimental rather than based on knowledge of basic mechanisms because the mechanisms are poorly understood. The Epilepsy Phenome/Genome Project (EPGP) is a large-scale, international, multi-institutional, collaborative research project aimed at advancing the understanding of the genetic basis of the most common forms of epilepsy. The overall goal of EPGP is to collect detailed, high quality phenotypic (i.e., characteristics of individuals, from the molecular level to the whole person) information on persons with epilepsy and to compare the phenotypic information with genomic information. EPGP will provide a resource that may lead to many discoveries related to the diagnosis and treatment of epilepsy, including the eventual development of new therapies based on a better understanding of causes of the disorder.
Trial information was received from ClinicalTrials.gov and was last updated in January 2014.
Information provided to ClinicalTrials.gov by University of California, San Francisco.